EP3442532A4 - Traitement du carcinome à cellules rénales à l'aide de lenvatinib et d'évérolimus - Google Patents

Traitement du carcinome à cellules rénales à l'aide de lenvatinib et d'évérolimus Download PDF

Info

Publication number
EP3442532A4
EP3442532A4 EP17782552.8A EP17782552A EP3442532A4 EP 3442532 A4 EP3442532 A4 EP 3442532A4 EP 17782552 A EP17782552 A EP 17782552A EP 3442532 A4 EP3442532 A4 EP 3442532A4
Authority
EP
European Patent Office
Prior art keywords
lenvatinib
everolimus
treatment
cell carcinoma
renal cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP17782552.8A
Other languages
German (de)
English (en)
Other versions
EP3442532A1 (fr
Inventor
Alton KREMER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eisai R&D Management Co Ltd
Original Assignee
Eisai R&D Management Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Management Co Ltd filed Critical Eisai R&D Management Co Ltd
Publication of EP3442532A1 publication Critical patent/EP3442532A1/fr
Publication of EP3442532A4 publication Critical patent/EP3442532A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EP17782552.8A 2016-04-15 2017-04-17 Traitement du carcinome à cellules rénales à l'aide de lenvatinib et d'évérolimus Withdrawn EP3442532A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662322916P 2016-04-15 2016-04-15
JP2016081787 2016-04-15
PCT/JP2017/015461 WO2017179739A1 (fr) 2016-04-15 2017-04-17 Traitement du carcinome à cellules rénales à l'aide de lenvatinib et d'évérolimus

Publications (2)

Publication Number Publication Date
EP3442532A1 EP3442532A1 (fr) 2019-02-20
EP3442532A4 true EP3442532A4 (fr) 2019-12-11

Family

ID=60041779

Family Applications (1)

Application Number Title Priority Date Filing Date
EP17782552.8A Withdrawn EP3442532A4 (fr) 2016-04-15 2017-04-17 Traitement du carcinome à cellules rénales à l'aide de lenvatinib et d'évérolimus

Country Status (7)

Country Link
EP (1) EP3442532A4 (fr)
KR (1) KR20180129795A (fr)
CN (1) CN108883106A (fr)
AU (1) AU2017249459A1 (fr)
CA (1) CA3019682A1 (fr)
SG (1) SG11201808774RA (fr)
WO (1) WO2017179739A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109793736A (zh) * 2019-01-31 2019-05-24 徐州医科大学 一种乐伐替尼在制备自然杀伤细胞激动剂中的应用
AU2021297151A1 (en) * 2020-06-17 2023-02-09 Eisai R&D Management Co., Ltd. Methods for treating cancer or von-Hippel Lindau disease using a combination of a PD-1 antagonist, a HIF-2 alpha inhibitor, and lenvatinib or a pharmaceutically acceptable salt thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS54033B1 (en) * 2003-12-25 2015-10-30 Eisai R&D Management Co. Ltd. CRYSTAL FORM OF THE SALTS 4- (3-CHLORO-4- (CYCLOPROPYLAMINOCARBONYL) AMINO-PHENOXY) -7-METHOXY-6-HINOLINKARBOXAMIDE OR ITS SOLVATES AND THE PROCESS FOR THEIR PRODUCTION

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
No further relevant documents disclosed *

Also Published As

Publication number Publication date
CA3019682A1 (fr) 2017-10-19
WO2017179739A1 (fr) 2017-10-19
EP3442532A1 (fr) 2019-02-20
KR20180129795A (ko) 2018-12-05
SG11201808774RA (en) 2018-11-29
CN108883106A (zh) 2018-11-23
AU2017249459A1 (en) 2018-10-25

Similar Documents

Publication Publication Date Title
EP3328399A4 (fr) Cellules modifiées et méthodes de thérapie
EP3325473A4 (fr) Composés et leurs utilisations dans le traitement de cancers et d'autres états médicaux
EP3200915A4 (fr) Biocharbons et processus de traitement de biocharbon
EP3253387A4 (fr) Composés et utilisations dans le traitement d' états associés à la sénescence
EP3432888A4 (fr) Traitement du cancer avec tg02
EP3114716A4 (fr) Cellules de batterie et agencements
EP3038610A4 (fr) Compositions et méthodes pour le traitement de la presbytie
EP3250682A4 (fr) Cellules à propriétés immuno-régulatrices augmentées et leurs procédés d'utilisation et de fabrication
EP3519833A4 (fr) Méthodes de pronostic et de traitement
EP3274720A4 (fr) Profilage moléculaire et fonctionnel intégré de cellules
EP3307329A4 (fr) Traitement et diagnostic du cancer
EP3245303A4 (fr) Cellules modifiées par l'âge et procédé de fabrication de cellules modifiées par l'âge
EP3233173A4 (fr) Système et procédé de perméabilité de cathéter
EP3148526A4 (fr) Utilisation de l'éribuline dans le traitement du cancer
EP3157336A4 (fr) Oxabicycloheptanes et oxabicycloheptènes pour le traitement du cancer des ovaires
EP3873613A4 (fr) Microarn modifiés par 5-halogéno-uracile et leur utilisation dans le traitement du cancer
EP3202909A4 (fr) Ribozyme à épissage spécifique du cancer, et son utilisation
EP3266803A4 (fr) Polymère et corps réticulé associé
EP3193875A4 (fr) Lévocétirizine et montélukast dans le traitement de troubles médiés par une inflammation
EP3226955A4 (fr) Cathéters à auto-ancrage et procédés d'utilisation
EP3112395A4 (fr) Polymère de coordination poreux et son application
EP3364987A4 (fr) Pronostic et traitement de carcinomes de cellules squameuses
EP3459581A4 (fr) Cathéter et dispositif de cathéter
EP3222721A4 (fr) Nouvel arnmi précurseur et application de ce dernier dans le traitement de tumeurs
EP3258964A4 (fr) Détection et traitement de tumeurs malignes dans le snc

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20181009

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20191112

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 9/20 20060101ALI20191106BHEP

Ipc: A61K 31/436 20060101ALI20191106BHEP

Ipc: A61P 35/00 20060101ALI20191106BHEP

Ipc: A61K 9/48 20060101ALI20191106BHEP

Ipc: A61K 31/47 20060101AFI20191106BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20210316

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230511

18W Application withdrawn

Effective date: 20240614